Cargando…

An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas

Background. We performed a retrospective study to assess whether the initial molecular characteristics of glioblastomas (GBMs) were associated with the response to the bevacizumab/irinotecan chemotherapy regimen given at recurrence. Results. Comparison of the genomic and gene expression profiles of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laffaire, Julien, Stefano, Anna Luisa Di, Chinot, Olivier, Idbaih, Ahmed, Gallego Perez-Larraya, Jaime, Marie, Yannick, Vintonenko, Nadia, Boisselier, Blandine, Farina, Patrizia, Delattre, Jean-Yves, Figarella-Branger, Dominique, Honnorat, Jérôme, Sanson, Marc, Ducray, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996912/ https://www.ncbi.nlm.nih.gov/pubmed/24804210 http://dx.doi.org/10.1155/2014/282815

Ejemplares similares

An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients
por: Ducray, François, et al.
Publicado: (2010)

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)

A phase III double-blind placebo-controlled randomized study of dexamphetamine sulfate for fatigue in primary brain tumors patients: An ANOCEF trial (DXA)
por: Laigle-Donadey, Florence, et al.
Publicado: (2019)

NOTCH2 Is Neither Rearranged nor Mutated in t(1;19) Positive Oligodendrogliomas
por: Benetkiewicz, Magdalena, et al.
Publicado: (2009)

Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guideline
por: Martz, Nicolas, et al.
Publicado: (2023)

Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?
por: Heng, Marie Amélie, et al.
Publicado: (2016)

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas
por: Grandin, Nathalie, et al.
Publicado: (2019)

Mitochondrial DNA copy number as a prognostic marker is age-dependent in adult glioblastoma
por: Sourty, Baptiste, et al.
Publicado: (2022)

Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas
por: Kamoun, Aurélie, et al.
Publicado: (2016)

Tumor and Endothelial Cell Hybrids Participate in Glioblastoma Vasculature
por: El Hallani, Soufiane, et al.
Publicado: (2014)

DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide
por: Etcheverry, Amandine, et al.
Publicado: (2014)

Correction: ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target
por: Bikeye, Sandra-Nadia Ngwabyt, et al.
Publicado: (2011)

ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target
por: Bikeye, Sandra-Nadia Ngwabyt, et al.
Publicado: (2010)

Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome
por: Appay, Romain, et al.
Publicado: (2018)

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
por: Ducray, François, et al.
Publicado: (2008)

Mutational analysis of primary central nervous system lymphoma
por: Bruno, Aurélie, et al.
Publicado: (2014)

Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults
por: Picart, Thiébaud, et al.
Publicado: (2021)

Polysialic Acid Neural Cell Adhesion Molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines
por: Amoureux, Marie-Claude, et al.
Publicado: (2010)

Prediction of Response to Temozolomide in Low‐Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics
por: Mazzocco, P, et al.
Publicado: (2015)

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial
por: Quillien, Véronique, et al.
Publicado: (2016)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
por: Cuppini, Lucia, et al.
Publicado: (2013)

TCF12 is mutated in anaplastic oligodendroglioma
por: Labreche, Karim, et al.
Publicado: (2015)

IDH Mutations: Genotype-Phenotype Correlation and Prognostic Impact
por: Wang, Xiao-Wei, et al.
Publicado: (2014)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo
por: Berges, Raphael, et al.
Publicado: (2014)

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
por: Jiguet-Jiglaire, Carine, et al.
Publicado: (2022)

An AI-Powered Blood Test to Detect Cancer Using NanoDSF
por: Tsvetkov, Philipp O., et al.
Publicado: (2021)

Achievement of Three Year Remission with Bevacizumab and Irinotecan in Recurrent Glioblastoma Multiforme: A Case Report
por: Vivekanandarajah, Abhirami, et al.
Publicado: (2011)

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
por: García-Alfonso, P, et al.
Publicado: (2010)

Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan
por: Aquino, Domenico, et al.
Publicado: (2014)

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
por: Garcia-Alfonso, Pilar, et al.
Publicado: (2015)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
por: Souglakos, J, et al.
Publicado: (2012)

Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool
por: Tsvetkov, Philipp O., et al.
Publicado: (2018)

Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation
por: Mazzocco, Pauline, et al.
Publicado: (2015)

Molecular heterogeneity of glioblastomas: does location matter?
por: Denicolaï, Emilie, et al.
Publicado: (2015)

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro
por: Graillon, Thomas, et al.
Publicado: (2017)

Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study
por: Garnier, Louis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l2ol90002melckujmqt9859cu0